IP Library › Granted Patent US 11,814,425
Granted Patent B2
US 11,814,425 · App. 16/784,970 · Granted Nov 14, 2023

Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof

Inventors: Rocco Jamie Rotello (Lebanon, OH); Kevin Gene Peters (Cincinnati, OH); Michael Glenn Davis (Lebanon, OH)
Assignee: Eye Point Pharmaceuticals, Inc.
C07K16/18C07K16/28C07K16/40A61K2039/505C07K2317/55C07K2317/73C07K2317/75C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,814,425
App. No.
16/784,970
Granted
Nov 14, 2023
Kind
B2
Abstract

Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTPβ), and uses thereof.

Claims (10)

1. An antibody or an antigen-binding fragment thereof that binds to human protein tyrosine phosphatase beta (HPTPβ), wherein the antibody or antigen-binding fragment thereof comprises antigen-binding region residues from an antibody produced by hybridoma cell line ATCC NO. PTA-7580 or a humanized form thereof, and wherein the antibody or antigen-binding fragment thereof enhances Tie-2 activation.

2. The antibody of claim 1 , wherein the antibody or antigen-binding fragment thereof binds a FN3 repeat of HPTPβ.

3. The antibody of claim 1 , wherein the antibody is a monoclonal antibody.

4. The antibody of claim 1 , wherein the antibody is an antibody produced by hybridoma cell line ATCC NO. PTA-7580 or a humanized form thereof.

5. The antibody of claim 1 , wherein the antibody or antigen-binding fragment thereof is humanized.

6. An antibody that binds to HPTPβ, wherein the antibody comprises antigen-binding region residues from an antibody produced by hybridoma cell line ATCC NO. PTA-7580 or a humanized form thereof, and wherein the antibody enhances Tie-2 activation.

7. The antibody of claim 6 , wherein the antibody binds a FN3 repeat of HPTPβ.

8. The antibody of claim 6 , wherein the antibody is a monoclonal antibody.

9. The antibody of claim 6 , wherein the antibody is an antibody produced by hybridoma cell line ATCC NO. PTA-7580 or a humanized form thereof.

10. The antibody of claim 6 , wherein the antibody is humanized.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2021
From: AERPIO PHARMACEUTICALS, INC.
To: EYEPOINT PHARMACEUTICALS, INC.
Reel/Frame 057448/0033 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2020
From: ROTELLO, ROCCO JAMIE; PETERS, KEVIN GENE; DAVIS, MICHAEL GLENN
To: AERPIO PHARMACEUTICALS, INC.
Reel/Frame 053817/0543 →
Cited By (1)
US 12,398,204